SG10201607369QA - Methods and means for the production of ig-like molecules - Google Patents
Methods and means for the production of ig-like moleculesInfo
- Publication number
- SG10201607369QA SG10201607369QA SG10201607369QA SG10201607369QA SG10201607369QA SG 10201607369Q A SG10201607369Q A SG 10201607369QA SG 10201607369Q A SG10201607369Q A SG 10201607369QA SG 10201607369Q A SG10201607369Q A SG 10201607369QA SG 10201607369Q A SG10201607369Q A SG 10201607369QA
- Authority
- SG
- Singapore
- Prior art keywords
- molecules
- production
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261635935P | 2012-04-20 | 2012-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201607369QA true SG10201607369QA (en) | 2016-10-28 |
Family
ID=48289584
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913634VA SG10201913634VA (en) | 2012-04-20 | 2013-04-19 | Methods and means for the production of ig-like molecules |
SG10201607371UA SG10201607371UA (en) | 2012-04-20 | 2013-04-19 | Methods and means for the production of ig-like molecules |
SG11201406772YA SG11201406772YA (en) | 2012-04-20 | 2013-04-19 | Methods and means for the production of ig-like molecules |
SG10201607369QA SG10201607369QA (en) | 2012-04-20 | 2013-04-19 | Methods and means for the production of ig-like molecules |
SG11201406770WA SG11201406770WA (en) | 2012-04-20 | 2013-04-19 | Methods and means for the production of ig-like molecules |
SG10201913376XA SG10201913376XA (en) | 2012-04-20 | 2013-04-19 | Methods and means for the production of ig-like molecules |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913634VA SG10201913634VA (en) | 2012-04-20 | 2013-04-19 | Methods and means for the production of ig-like molecules |
SG10201607371UA SG10201607371UA (en) | 2012-04-20 | 2013-04-19 | Methods and means for the production of ig-like molecules |
SG11201406772YA SG11201406772YA (en) | 2012-04-20 | 2013-04-19 | Methods and means for the production of ig-like molecules |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201406770WA SG11201406770WA (en) | 2012-04-20 | 2013-04-19 | Methods and means for the production of ig-like molecules |
SG10201913376XA SG10201913376XA (en) | 2012-04-20 | 2013-04-19 | Methods and means for the production of ig-like molecules |
Country Status (24)
Country | Link |
---|---|
US (11) | US9248182B2 (en) |
EP (4) | EP2838917B1 (en) |
JP (7) | JP6272299B2 (en) |
KR (8) | KR20200126007A (en) |
CN (5) | CN114163530A (en) |
AU (4) | AU2013249985B2 (en) |
CA (2) | CA2870821C (en) |
CY (2) | CY1122153T1 (en) |
DK (2) | DK2838917T3 (en) |
EA (3) | EA202090591A3 (en) |
ES (2) | ES2740749T3 (en) |
HK (2) | HK1206039A1 (en) |
HR (2) | HRP20191409T1 (en) |
HU (2) | HUE045944T2 (en) |
LT (2) | LT2838918T (en) |
MX (4) | MX360110B (en) |
NZ (4) | NZ799532A (en) |
PL (2) | PL2838917T3 (en) |
PT (2) | PT2838917T (en) |
RS (2) | RS59260B1 (en) |
SG (6) | SG10201913634VA (en) |
SI (2) | SI2838917T1 (en) |
WO (2) | WO2013157953A1 (en) |
ZA (2) | ZA201407835B (en) |
Families Citing this family (377)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
DK2314629T4 (en) | 2002-07-18 | 2023-02-06 | Merus Nv | RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES |
AU2004242614B2 (en) | 2003-05-30 | 2011-09-22 | Merus N.V. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
JP5620626B2 (en) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | Polypeptide production method by association control |
EP4001409A1 (en) | 2006-03-31 | 2022-05-25 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
CN102719444B (en) | 2006-09-01 | 2016-12-14 | 人类多细胞株治疗学公司 | The expression that people or Humanized immunoglobulin strengthen in non-human transgenic animal |
EA017203B1 (en) | 2006-09-07 | 2012-10-30 | Круселл Холланд Б.В. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
KR102467302B1 (en) | 2007-09-26 | 2022-11-14 | 추가이 세이야쿠 가부시키가이샤 | Modified antibody constant region |
DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US20120071634A1 (en) | 2009-03-19 | 2012-03-22 | Chugai Seiyaku Kabushiki Kaisha | Antibody Constant Region Variant |
PT2417156E (en) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Trivalent, bispecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
SG179196A1 (en) | 2009-09-16 | 2012-04-27 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
US8637641B2 (en) | 2010-07-29 | 2014-01-28 | Xencor, Inc. | Antibodies with modified isoelectric points |
US9334331B2 (en) | 2010-11-17 | 2016-05-10 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibodies |
CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
CN103502271B (en) | 2011-02-28 | 2016-10-26 | 霍夫曼-拉罗奇有限公司 | Antigen-binding proteins |
EP2694092B1 (en) | 2011-04-08 | 2017-01-04 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
PT3572517T (en) | 2011-08-05 | 2021-06-23 | Regeneron Pharma | Humanized universal light chain mice |
JP6159724B2 (en) | 2011-08-23 | 2017-07-05 | ロシュ グリクアート アーゲー | Bispecific antibodies and tumor antigens specific for T cell activating antigens and methods of use |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
CA2853230C (en) | 2011-10-31 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
BR112014018575A2 (en) * | 2012-01-26 | 2017-07-04 | Amgen Inc | Growth Differentiation Factor 15 Polypeptides (gdf-15) |
CN114163530A (en) | 2012-04-20 | 2022-03-11 | 美勒斯公司 | Methods and means for producing immunoglobulin-like molecules |
BR112015000167B1 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | DIMERIC PROTEIN, PROTEIN, COMPOSITION, KIT OF PARTS AND THEIR USES, AS WELL AS A METHOD TO INCREASE THE OLIGOMERIZATION IN SOLUTION OF A DIMERIC PROTEIN COMPRISING A FIRST AND SECOND POLYPEPTIDE, EACH COMPRISING AT LEAST ONE CH2 AND CH3 REGIONS HUMAN AND VARIANT DIMER PROTEIN |
PL2900694T3 (en) | 2012-09-27 | 2018-12-31 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
CA2879768A1 (en) | 2012-10-08 | 2014-04-17 | Roche Glycart Ag | Fc-free antibodies comprising two fab-fragments and methods of use |
CA2892623C (en) | 2012-11-27 | 2020-08-11 | Ajou University Industry-Academic Cooperation Foundation | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
AU2014205086B2 (en) | 2013-01-14 | 2019-04-18 | Xencor, Inc. | Novel heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
AU2014207549B2 (en) | 2013-01-15 | 2018-12-06 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
EP2961773B1 (en) | 2013-02-26 | 2019-03-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
EP3708584A1 (en) | 2013-02-26 | 2020-09-16 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10544187B2 (en) | 2013-03-15 | 2020-01-28 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
EP3878866A1 (en) | 2013-04-29 | 2021-09-15 | F. Hoffmann-La Roche AG | Fc-receptor binding modified asymmetric antibodies and methods of use |
SG10201810481UA (en) | 2013-04-29 | 2018-12-28 | Hoffmann La Roche | Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases |
WO2014177460A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
PT3027642T (en) | 2013-07-31 | 2020-10-30 | Amgen Inc | Growth differentiation factor 15 (gdf-15) constructs |
RU2758952C1 (en) | 2013-09-27 | 2021-11-03 | Чугаи Сейяку Кабусики Кайся | Method for producing a polypeptide heteromultimer |
JP6422956B2 (en) | 2013-10-11 | 2018-11-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Multispecific domain exchange common variable light chain antibody |
CR20160270A (en) | 2013-12-20 | 2016-09-05 | Hoffmann La Roche | ANTI-TAU ANTIBODIES (pS422) HUMANIZED AND USED METHODS |
US10561737B2 (en) | 2014-01-03 | 2020-02-18 | Hoffmann-La Roche Inc. | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
CN111057147B (en) | 2014-01-06 | 2023-11-10 | 豪夫迈·罗氏有限公司 | Monovalent blood brain barrier shuttle module |
KR20160107190A (en) | 2014-01-15 | 2016-09-13 | 에프. 호프만-라 로슈 아게 | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
SG11201607109QA (en) | 2014-02-28 | 2016-09-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
SI3110849T1 (en) | 2014-02-28 | 2021-01-29 | Merus N.V. | Antibody that binds erbb-2 and erbb-3 |
CN106255410B (en) | 2014-03-21 | 2020-01-10 | 瑞泽恩制药公司 | Non-human animals producing single domain binding proteins |
AP2016009475A0 (en) | 2014-03-28 | 2016-09-30 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
EP3126389A1 (en) | 2014-04-02 | 2017-02-08 | F. Hoffmann-La Roche AG | Method for detecting multispecific antibody light chain mispairing |
UA117289C2 (en) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Multispecific antibodies |
AR100978A1 (en) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
EP3164419A1 (en) | 2014-06-26 | 2017-05-10 | F. Hoffmann-La Roche AG | Anti-brdu antibodies and methods of use |
EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
CA2951599A1 (en) | 2014-08-04 | 2016-02-11 | F. Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
AU2015329965A1 (en) | 2014-10-09 | 2017-04-27 | Engmab Sàrl | Bispecific antibodies against CD3epsilon and ROR1 |
PT3215528T (en) | 2014-11-06 | 2019-10-11 | Hoffmann La Roche | Fc-region variants with modified fcrn-binding and methods of use |
WO2016071377A1 (en) | 2014-11-06 | 2016-05-12 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and protein a-binding properties |
EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
DK3221355T3 (en) | 2014-11-20 | 2020-12-07 | Hoffmann La Roche | Combination therapy with T cell activating bispecific antigen binding molecules CD3 and folate receptor 1 (FolR1) as well as PD-1 axis binding antagonists |
MX2017006918A (en) | 2014-11-26 | 2018-01-25 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd38. |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
PE20171324A1 (en) | 2014-11-26 | 2017-09-11 | Xencor Inc | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS |
JP6721590B2 (en) | 2014-12-03 | 2020-07-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Multispecific antibody |
WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
CN110655582B (en) * | 2015-01-08 | 2022-12-16 | 江苏康宁杰瑞生物制药有限公司 | Bispecific antibodies or antibody mixtures with a common light chain |
WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
CA2979702A1 (en) | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
KR20170129233A (en) * | 2015-03-26 | 2017-11-24 | 악셀레론 파마 인코포레이티드 | Polistatin-related fusion proteins and uses thereof |
JP7082484B2 (en) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | Method for Producing Polypeptide Heterogeneous Multimer |
CN113929779A (en) | 2015-06-24 | 2022-01-14 | 豪夫迈·罗氏有限公司 | Humanized anti-Tau (pS422) antibodies and methods of use |
CA2991880A1 (en) | 2015-07-10 | 2017-01-19 | Merus N.V. | Human cd3 binding antibody |
LT3319993T (en) | 2015-07-10 | 2020-05-11 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
EP3322727A1 (en) | 2015-07-15 | 2018-05-23 | Genmab A/S | Humanized or chimeric cd3 antibodies |
EP3307321A4 (en) | 2015-08-26 | 2019-04-17 | Bison Therapeutics Inc. | Multispecific antibody platform and related methods |
AR106188A1 (en) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE |
WO2017055393A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules |
EP3356417A1 (en) | 2015-10-02 | 2018-08-08 | H. Hoffnabb-La Roche Ag | Bispecific t cell activating antigen binding molecules binding mesothelin and cd3 |
RU2729371C1 (en) | 2015-10-02 | 2020-08-06 | Ф. Хоффманн-Ля Рош Аг | Bispecific antibodies specific to pd1 and tim3 |
WO2017055385A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xgd2 bispecific t cell activating antigen binding molecules |
CR20180162A (en) | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | BISPECIFIC MOLECULES OF ANTIGEN BINDING TO T-CELL ACTIVATORS |
US20180282410A1 (en) | 2015-10-02 | 2018-10-04 | Hoffmann-La Roche Inc. | Anti-cd3xrob04 bispecific t cell activating antigen binding molecules |
CN108026177B (en) | 2015-10-02 | 2021-11-26 | 豪夫迈·罗氏有限公司 | Bispecific anti-CD 19XCD 3T cell activating antigen binding molecules |
WO2017055392A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules |
EP3150637A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Multispecific antibodies |
WO2017055399A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Cellular based fret assay for the determination of simultaneous binding |
US20170096495A1 (en) | 2015-10-02 | 2017-04-06 | Hoffmann-La Roche Inc. | Bispecific t cell activating antigen binding molecules |
KR101851380B1 (en) | 2015-10-12 | 2018-04-23 | 아주대학교산학협력단 | Method to generate CH3 domain mutant pairs of heterodimeric Fc using yeast mating and CH3 domain mutant pairs thereby |
CN115925944A (en) | 2015-10-23 | 2023-04-07 | 美勒斯公司 | Binding molecules for inhibiting cancer growth |
MX2018005036A (en) | 2015-10-29 | 2018-08-01 | Hoffmann La Roche | Anti-variant fc-region antibodies and methods of use. |
CN113897371A (en) * | 2015-10-29 | 2022-01-07 | 豪夫迈·罗氏有限公司 | Transgenic rabbits with common light chain |
EP3387013B1 (en) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
CN115920030A (en) | 2015-12-09 | 2023-04-07 | 豪夫迈·罗氏有限公司 | Use of type II anti-CD 20 antibodies for reducing anti-drug antibody formation |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
CN106883297B (en) * | 2015-12-16 | 2019-12-13 | 苏州康宁杰瑞生物科技有限公司 | CH3 domain-based heterodimer molecule, preparation method and application thereof |
KR20180091918A (en) | 2015-12-28 | 2018-08-16 | 추가이 세이야쿠 가부시키가이샤 | A method for efficiently purifying the Fc region-containing polypeptide |
CA3006529A1 (en) | 2016-01-08 | 2017-07-13 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
MX2018010988A (en) | 2016-03-14 | 2019-01-21 | Chugai Pharmaceutical Co Ltd | Cell injury inducing therapeutic drug for use in cancer therapy. |
CA3016563A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
DK3433280T3 (en) | 2016-03-22 | 2023-06-19 | Hoffmann La Roche | Protease-activated T-cell bispecific molecules |
WO2017186853A1 (en) * | 2016-04-27 | 2017-11-02 | Bcrt Holding Bv | T cell-based bi-specific immunotherapeutics |
BR112018069890A2 (en) | 2016-05-02 | 2019-02-05 | Hoffmann La Roche | target-specific fusion polypeptide, dimeric fusion polypeptide, isolated nucleic acid, isolated nucleic acid pair, host cell, method for producing a fusion polypeptide, immunoconjugate, pharmaceutical formulation, fusion polypeptide and use of the fusion polypeptide |
WO2017205014A1 (en) * | 2016-05-26 | 2017-11-30 | Qilu Puget Sound Biotherapeutics Corporation | Mixtures of antibodies |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
RU2767357C2 (en) | 2016-06-14 | 2022-03-17 | Ксенкор, Инк. | Bispecific checkpoint inhibitors antibodies |
CA3029328A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
CN109415435B (en) | 2016-07-04 | 2024-01-16 | 豪夫迈·罗氏有限公司 | Novel antibody forms |
KR20240017129A (en) | 2016-07-14 | 2024-02-06 | 젠맵 에이/에스 | Multispecific antibodies against cd40 and cd137 |
KR102050463B1 (en) | 2016-08-10 | 2019-11-29 | 아주대학교산학협력단 | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
EA201990578A1 (en) | 2016-09-23 | 2019-10-31 | BINDING MOLECULES THAT MODULATE THE CELL BIOLOGICAL ACTIVITY | |
IL265605B1 (en) * | 2016-09-29 | 2024-02-01 | Beijing Hanmi Pharmaceutical Co Ltd | Heterodimeric immunoglobulin constructs, pharmaceutical composition comprising the same, use and preparation methods thereof |
JP6785372B2 (en) | 2016-09-30 | 2020-11-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | SPR-based double bond assay for functional analysis of multispecific molecules |
PL3519437T3 (en) | 2016-09-30 | 2022-01-17 | F. Hoffmann-La Roche Ag | Bispecific antibodies against p95her2 |
WO2018071919A1 (en) | 2016-10-14 | 2018-04-19 | Xencor, Inc. | IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS |
CA3041254A1 (en) * | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
WO2018083126A1 (en) | 2016-11-01 | 2018-05-11 | Genmab B.V. | Polypeptide variants and uses thereof |
TW201829463A (en) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | Anti-hla-g antibodies and use thereof |
US11319378B2 (en) | 2016-11-18 | 2022-05-03 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same |
US11111305B2 (en) | 2017-01-09 | 2021-09-07 | Torch Therapeutics | Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex |
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
BR112019015900A2 (en) | 2017-02-10 | 2020-04-07 | Genmab B.V. | polypeptide, methods to increase the agonistic activity of a polypeptide, to increase the cdc activity of a polypeptide and to treat an individual having a disease, composition, kit of parts, and, use of a polypeptide or composition |
US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
AU2018220736A1 (en) | 2017-02-20 | 2019-09-05 | Dragonfly Therapeutics, Inc. | Proteins binding HER2, NKG2D and CD16 |
AU2018231618A1 (en) | 2017-03-09 | 2019-10-03 | Genmab A/S | Antibodies against PD-L1 |
RU2750721C2 (en) | 2017-03-10 | 2021-07-01 | Ф. Хоффманн-Ля Рош Аг | Method for the production of multi-specific antibodies |
WO2018182422A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
CA3058342A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour |
WO2018182420A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Antibodies for the treatment of erbb-2/erbb-3 positive tumors |
US20200270359A1 (en) | 2017-03-31 | 2020-08-27 | Genmab Holding B.V. | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof |
BR112019020448A2 (en) | 2017-04-01 | 2020-06-09 | Beijing hanmi pharm co ltd | bispecific heterodimeric antibody similar to the structure of the natural anti-pd-l1 / anti-pd-1 antibody and preparation thereof |
BR112019018767A2 (en) | 2017-04-03 | 2020-05-05 | Hoffmann La Roche | antibodies, bispecific antigen binding molecule, one or more isolated polynucleotides, one or more vectors, host cell, method for producing an antibody, pharmaceutical composition, uses, method for treating a disease in an individual and invention |
WO2018184965A1 (en) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody |
ES2928718T3 (en) | 2017-04-03 | 2022-11-22 | Hoffmann La Roche | Immunoconjugates of an anti-PD-1 antibody with a mutant IL-2 or with IL-15 |
KR102346336B1 (en) | 2017-04-05 | 2022-01-04 | 에프. 호프만-라 로슈 아게 | Bispecific antibodies that specifically bind to PD1 and LAG3 |
JOP20190222A1 (en) | 2017-04-11 | 2019-09-24 | Zymeworks Inc | Anti-pd-l1-anti-tim-3 bispecific antibodies |
CA3058279A1 (en) | 2017-04-13 | 2018-10-18 | F.Hoffmann-La Roche Ag | An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer |
EA201992522A1 (en) | 2017-05-17 | 2020-04-22 | Мерус Н.В. | COMBINATION OF THE SPECIFIC ANTIBODY TO ErbB-2 / ErbB-3 WITH ENDOCRINE THERAPY OF BREAST CANCER |
WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
KR20200014304A (en) | 2017-06-02 | 2020-02-10 | 에프. 호프만-라 로슈 아게 | Type II anti-CD20 antibodies and anti-CD20 / anti-CD3 bispecific antibodies for the treatment of cancer |
MA49259A (en) | 2017-06-07 | 2020-04-15 | Genmab Bv | THERAPEUTIC ANTIBODIES BASED ON MUTATED IGG HEXAMERS |
EP3638700A4 (en) * | 2017-06-14 | 2021-04-21 | Dingfu Biotarget Co., Ltd | Proteinaceous heterodimer and use thereof |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
CN111132733A (en) | 2017-06-30 | 2020-05-08 | Xencor股份有限公司 | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15R α and an antigen binding domain |
TW201920657A (en) | 2017-07-06 | 2019-06-01 | 荷蘭商米樂斯股份有限公司 | Antibodies that modulate a biological activity expressed by a cell |
TW201920264A (en) * | 2017-07-06 | 2019-06-01 | 荷蘭商米樂斯股份有限公司 | Binding molecules that modulate a biological activity expressed by a cell |
IL271833B1 (en) | 2017-07-06 | 2024-05-01 | Merus Nv | Antibodies that modulate a biological activity expressed by a cell |
AR112603A1 (en) | 2017-07-10 | 2019-11-20 | Lilly Co Eli | BIS SPECIFIC ANTIBODIES CONTROL POINT INHIBITORS |
WO2019014912A1 (en) * | 2017-07-21 | 2019-01-24 | 赵磊 | Heterodimeric protein and preparation method thereof |
AU2018309339A1 (en) | 2017-08-04 | 2020-02-20 | BioNTech SE | Binding agents binding to PD-L1 and CD137 and use thereof |
EP3665198A1 (en) | 2017-08-09 | 2020-06-17 | Merus N.V. | Antibodies that bind egfr and cmet |
TW201930351A (en) | 2017-10-06 | 2019-08-01 | 日商小野藥品工業股份有限公司 | Bispecific antibody |
MX2020003497A (en) | 2017-10-20 | 2020-07-22 | Hoffmann La Roche | Method for generating multispecific antibodies from monospecific antibodies. |
WO2019086362A1 (en) | 2017-10-30 | 2019-05-09 | F. Hoffmann-La Roche Ag | Method for in vivo generation of multispecific antibodies from monospecific antibodies |
JP2021500902A (en) | 2017-11-01 | 2021-01-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | New TNF family ligand trimer-containing antigen-binding molecule |
KR102559706B1 (en) | 2017-11-01 | 2023-07-25 | 에프. 호프만-라 로슈 아게 | TRIFAB-Contols Body |
WO2019086500A2 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | Bispecific 2+1 contorsbodies |
CN111295392A (en) | 2017-11-01 | 2020-06-16 | 豪夫迈·罗氏有限公司 | Compbody-multivalent target binders |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CN112272563A (en) | 2017-11-08 | 2021-01-26 | Xencor股份有限公司 | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
EP3717008A1 (en) | 2017-12-01 | 2020-10-07 | Merus N.V. | Use of bispecific antibody and il-15 for combination therapy |
SG11202005216XA (en) * | 2017-12-04 | 2020-07-29 | Beijing Hanmi Pharmaceutical Co Ltd | Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof |
KR20200100098A (en) | 2017-12-19 | 2020-08-25 | 젠코어 인코포레이티드 | Engineered IL-2 FC fusion protein |
SG11202005632SA (en) | 2017-12-21 | 2020-07-29 | Hoffmann La Roche | Antibodies binding to hla-a2/wt1 |
JP7074859B2 (en) | 2017-12-22 | 2022-05-24 | エフ.ホフマン-ラ ロシュ アーゲー | Method of depletion of light chain mismatched antibody variants by hydrophobic interaction chromatography |
EP3743440A1 (en) | 2018-01-24 | 2020-12-02 | Genmab B.V. | Polypeptide variants and uses thereof |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
CN111699004A (en) | 2018-02-06 | 2020-09-22 | 豪夫迈·罗氏有限公司 | Treatment of ophthalmic disorders |
WO2019153200A1 (en) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof |
BR112020016169A2 (en) | 2018-02-08 | 2020-12-15 | Genentech, Inc. | MOLECULES FOR BINDING THE BIESPECIFIC ANTIGEN, INSULATED NUCLEIC ACID, VECTOR, HOSTING CELL, METHODS FOR PRODUCING THE BINDING MOLECULE, SET OF NUCLEIC ACIDS, ISOLATED, VEGETABLE CONTAINER, VEGETABLE CONTAINERS, TO TREAT OR DELAY CANCER PROGRESSION, METHODS TO IMPROVE THE IMMUNE FUNCTION AND KIT |
MX2020008336A (en) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor. |
TWI829667B (en) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | Antibodies binding to gprc5d |
TW202340257A (en) | 2018-02-09 | 2023-10-16 | 日商小野藥品工業股份有限公司 | Bispecific antibody |
WO2019154349A1 (en) * | 2018-02-11 | 2019-08-15 | 北京韩美药品有限公司 | Anti-pd-1/anti-vegf natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof |
EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
EP3765516A2 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
TW202003569A (en) | 2018-03-30 | 2020-01-16 | 荷蘭商美勒斯公司 | Multivalent antibody |
WO2019195623A2 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
AU2019253462A1 (en) | 2018-04-09 | 2020-11-26 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
JP2021521784A (en) | 2018-04-18 | 2021-08-30 | ゼンコア インコーポレイテッド | PD-1 targeted heterodimer fusion proteins containing IL-15 / IL-15RaFc fusion proteins and PD-1 antigen binding domains and their use |
AR115052A1 (en) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM |
KR20210003814A (en) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | TIM-3 targeting heterodimer fusion protein containing IL-15/IL-15Rα Fc-fusion protein and TIM-3 antigen binding domain |
MX2020011552A (en) | 2018-05-03 | 2020-11-24 | Genmab Bv | Antibody variant combinations and uses thereof. |
EP3793599A1 (en) | 2018-05-16 | 2021-03-24 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
AU2019276578A1 (en) | 2018-06-01 | 2021-01-14 | Compugen Ltd | Anti-PVRIG/anti-TIGIT bispecific antibodies and methods of use |
TW202016151A (en) | 2018-06-09 | 2020-05-01 | 德商百靈佳殷格翰國際股份有限公司 | Multi-specific binding proteins for cancer treatment |
EP3810194A1 (en) | 2018-06-22 | 2021-04-28 | Genmab Holding B.V. | Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof |
DE202019005887U1 (en) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
EP3820890A1 (en) | 2018-07-13 | 2021-05-19 | Genmab A/S | Trogocytosis-mediated therapy using cd38 antibodies |
KR20210031932A (en) | 2018-07-13 | 2021-03-23 | 젠맵 에이/에스 | Variants of CD38 antibody and uses thereof |
GB2576914A (en) | 2018-09-06 | 2020-03-11 | Kymab Ltd | Antigen-binding molecules comprising unpaired variable domains produced in mammals |
US20220111043A1 (en) | 2018-09-19 | 2022-04-14 | Lava Therapeutics B.V. | Dual acting cd1d immunoglobulin |
WO2020072821A2 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
SG11202103100SA (en) | 2018-10-04 | 2021-04-29 | Genmab Holding B V | Pharmaceutical compositions comprising bispecific anti-cd37 antibodies |
AU2019366956A1 (en) | 2018-10-23 | 2021-05-20 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
MX2021004774A (en) | 2018-10-29 | 2021-08-24 | Hoffmann La Roche | Antibody formulation. |
BR112021008774A2 (en) | 2018-11-06 | 2021-11-30 | BioNTech SE | Pharmaceutical formulation, binding agent, methods for treating a disease, for producing a pharmaceutical formulation, for inducing cell death or inhibiting the growth and/or proliferation of a tumor cell, and, use of a pharmaceutical formulation |
CA3121699A1 (en) | 2018-12-05 | 2020-06-11 | Morphosys Ag | Multispecific antigen-binding molecules |
GB201820687D0 (en) | 2018-12-19 | 2019-01-30 | Kymab Ltd | Antagonists |
MA54525A (en) | 2018-12-20 | 2021-10-27 | Merus Nv | CLEC12AXCD3 BISPECIFIC ANTIBODIES AND METHODS OF TREATING A DISEASE |
DK3723858T3 (en) | 2018-12-21 | 2022-01-24 | Kymab Ltd | FIXAXFX BISPECIFIC ANTIBODY WITH COMMON LIGHT CHAIN |
AU2019410075B2 (en) | 2018-12-21 | 2022-08-25 | F. Hoffmann-La Roche Ag | Antibodies binding to CD3 |
EP3902560A1 (en) | 2018-12-28 | 2021-11-03 | F. Hoffmann-La Roche AG | A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response |
MA54643A (en) | 2018-12-31 | 2021-11-10 | Merus Nv | MULTIVALENT TRUNCATED MULTIMERS |
EP3906255A1 (en) | 2018-12-31 | 2021-11-10 | Merus N.V. | Mixed binding domains |
TW202043256A (en) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | Prostate neoantigens and their uses |
NL2022494B1 (en) | 2019-02-01 | 2020-08-19 | Lava Therapeutics B V | Novel CD40-binding antibodies |
US20220135694A1 (en) | 2019-02-01 | 2022-05-05 | Lava Therapeutics B.V. | Novel cd40-binding antibodies |
CN114409798A (en) * | 2019-02-14 | 2022-04-29 | 美勒斯公司 | Preparation of a composition comprising two or more antibodies |
MX2021009769A (en) * | 2019-02-14 | 2021-09-08 | Merus Nv | Producing compositions comprising two or more antibodies. |
US20220127376A1 (en) | 2019-02-14 | 2022-04-28 | Merus N.V. | Combinations of binding moieties that bind egfr, her2 and her3 |
SG11202109122SA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Anti-tcr antibody molecules and uses thereof |
JP2022522662A (en) | 2019-02-21 | 2022-04-20 | マレンゴ・セラピューティクス,インコーポレーテッド | Multifunctional molecules that bind to T cells and their use for treating autoimmune disorders |
JP2022521750A (en) | 2019-02-21 | 2022-04-12 | マレンゴ・セラピューティクス,インコーポレーテッド | Multifunctional molecule that binds to calreticulin and its use |
SG11202109061YA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
GB2597851B (en) | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
MX2021010390A (en) | 2019-03-01 | 2021-11-17 | Xencor Inc | Heterodimeric antibodies that bind enpp3 and cd3. |
EP3946354A4 (en) * | 2019-03-28 | 2023-01-11 | Ab Studio Inc. | Heteromultimeric proteins and methods of use thereof |
CN113677701A (en) | 2019-03-29 | 2021-11-19 | 豪夫迈·罗氏有限公司 | Method for generating affinity binding multispecific antibodies |
JP7249432B2 (en) | 2019-03-29 | 2023-03-30 | エフ. ホフマン-ラ ロシュ アーゲー | SPR-based binding assays for functional analysis of multivalent molecules |
TW202039578A (en) | 2019-03-29 | 2020-11-01 | 荷蘭商美勒斯公司 | Cd3 binding molecules |
AU2020261250A1 (en) | 2019-04-25 | 2021-10-14 | F. Hoffmann-La Roche Ag | Generation of antibody-derived polypeptides by polypeptide chain exchange |
CN113767114A (en) | 2019-04-25 | 2021-12-07 | 豪夫迈·罗氏有限公司 | Activatable therapeutic multispecific polypeptides with extended half-lives |
MX2021012872A (en) | 2019-04-25 | 2021-11-17 | Hoffmann La Roche | Therapeutic multispecific polypeptides activated by polypeptide chain exchange. |
EP3966241A1 (en) | 2019-05-09 | 2022-03-16 | Genmab B.V. | Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer |
CN114702587A (en) * | 2019-05-09 | 2022-07-05 | 美勒斯公司 | Variant domains and their isolation for multimerizing proteins |
JP7273195B2 (en) | 2019-05-13 | 2023-05-12 | エフ. ホフマン-ラ ロシュ アーゲー | Interference suppression pharmacokinetic immunoassay |
JP7317353B2 (en) * | 2019-06-18 | 2023-07-31 | 株式会社プロテイン・エクスプレス | Production of heterodimeric proteins by Brevibacillus |
MX2021015536A (en) | 2019-06-19 | 2022-02-10 | Hoffmann La Roche | Method for the generation of a protein expressing cell by targeted integration using cre mrna. |
EP3990646A1 (en) | 2019-06-26 | 2022-05-04 | F. Hoffmann-La Roche AG | Mammalian cell lines with sirt-1 gene knockout |
TW202115115A (en) | 2019-07-02 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | Immunoconjugates |
EP3998081A4 (en) | 2019-07-05 | 2023-07-12 | Ono Pharmaceutical Co., Ltd. | Treatment of hematologic cancer with pd-1/cd3 dual specificity protein |
AR119393A1 (en) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | ANTIBODIES THAT BIND NKG2D |
UY38803A (en) | 2019-07-26 | 2021-01-29 | Janssen Biotech Inc | PROTEINS INCLUDING CALICREIN-RELATED PEPTIDASE 2 ANTIGEN BINDING DOMAINS AND USES |
TW202118790A (en) | 2019-07-30 | 2021-05-16 | 日商小野藥品工業股份有限公司 | Bispecific antibody |
CA3144524A1 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Antibodies binding to gprc5d |
CN114174338A (en) | 2019-07-31 | 2022-03-11 | 豪夫迈·罗氏有限公司 | Antibodies that bind to GPRC5D |
EP4011918A4 (en) | 2019-08-08 | 2023-08-23 | ONO Pharmaceutical Co., Ltd. | Dual-specific protein |
CA3148121A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Materials and methods for improved single chain variable fragments |
JP2022545457A (en) | 2019-08-19 | 2022-10-27 | メルス ナムローゼ フェンノートシャップ | Treatment of cancer with a combination of an antibody that binds LGR5 and EGFR and a topoisomerase I inhibitor |
EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
TW202130664A (en) | 2019-10-24 | 2021-08-16 | 荷蘭商美勒斯公司 | Means and methods for treating subjects with her2 and her3 positive cancer |
JP2023500686A (en) | 2019-11-01 | 2023-01-10 | インノコア テクノロジーズ ビー.ブイ. | Dosage form for extended release of antibodies or large proteins |
EP4055046A1 (en) | 2019-11-06 | 2022-09-14 | Genmab B.V. | Antibody variant combinations and uses thereof |
WO2021113297A1 (en) | 2019-12-02 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
WO2021122875A1 (en) | 2019-12-18 | 2021-06-24 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a2/mage-a4 |
IL293310A (en) | 2019-12-18 | 2022-07-01 | Hoffmann La Roche | Bispecific anti-ccl2 antibodies |
TWI766512B (en) | 2020-01-02 | 2022-06-01 | 瑞士商赫孚孟拉羅股份公司 | Method for determining the amount of a therapeutic antibody in the brain |
EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics Inc | Multifunctional molecules that bind to cd33 and uses thereof |
JP2023510397A (en) | 2020-01-16 | 2023-03-13 | ジェンマブ エー/エス | Formulations of CD38 antibodies and uses thereof |
KR20220133196A (en) | 2020-01-29 | 2022-10-04 | 메뤼스 엔.페. | Means and methods for modulating the effects of immune cell involvement |
KR20220144377A (en) | 2020-01-30 | 2022-10-26 | 우모자 바이오파마 인코포레이티드 | Bispecific transduction promoter |
WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
TW202144388A (en) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | Neoantigens expressed in ovarian cancer and their uses |
TW202144389A (en) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | Neoantigens expressed in multiple myeloma and their uses |
PE20230001A1 (en) | 2020-03-13 | 2023-01-05 | Janssen Biotech Inc | MATERIALS AND METHODS FOR THE LINK OF SIGLEC-3/CD33 |
JP2023517753A (en) | 2020-03-18 | 2023-04-26 | ジェンマブ エー/エス | Antibody that binds to B7H4 |
WO2021190980A1 (en) | 2020-03-22 | 2021-09-30 | Quadrucept Bio Limited | Multimers for viral strain evolution |
US20230203466A1 (en) * | 2020-04-03 | 2023-06-29 | Medgenome Inc. | Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment |
KR20230004494A (en) | 2020-04-15 | 2023-01-06 | 에프. 호프만-라 로슈 아게 | immunoconjugate |
WO2021215926A1 (en) | 2020-04-24 | 2021-10-28 | Merus N.V. | Treatment of cancers with an antibody that binds lgr5 and egfr |
CA3180321A1 (en) | 2020-04-24 | 2021-10-28 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
BR112022020673A2 (en) | 2020-04-30 | 2023-01-24 | Bristol Myers Squibb Co | METHODS OF TREATMENT OF ADVERSE EVENTS RELATED TO CYTOKINE |
WO2021231278A1 (en) | 2020-05-11 | 2021-11-18 | F. Hoffmann-La Roche Ag | Combination therapy with modified pbmcs and an immunoconjugate |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
CN116462766A (en) | 2020-05-21 | 2023-07-21 | 美勒斯公司 | Methods and means for producing IG-like molecules |
CA3184189A1 (en) | 2020-05-27 | 2021-12-02 | Janssen Biotech, Inc. | Proteins comprising cd3 antigen binding domains and uses thereof |
JP2023529981A (en) | 2020-06-19 | 2023-07-12 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Immunostimulatory Fc domain binding molecules |
IL298402A (en) | 2020-06-19 | 2023-01-01 | Hoffmann La Roche | Antibodies binding to cd3 and cd19 |
WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
TW202216767A (en) | 2020-06-19 | 2022-05-01 | 瑞士商赫孚孟拉羅股份公司 | Antibodies binding to cd3 and folr1 |
AR122658A1 (en) | 2020-06-19 | 2022-09-28 | Hoffmann La Roche | ANTIBODIES THAT BIND TO CD3 |
WO2022008646A1 (en) | 2020-07-08 | 2022-01-13 | LAVA Therapeutics N.V. | Antibodies that bind psma and gamma-delta t cell receptors |
JP2023534726A (en) | 2020-07-23 | 2023-08-10 | ジェンマブ ビー.ブイ. | Combining anti-DR5 antibodies with immunomodulatory imide drugs for use in treating multiple myeloma |
CA3190307A1 (en) | 2020-07-29 | 2022-02-03 | Janssen Biotech, Inc. | Proteins comprising hla-g antigen binding domains and their uses |
CA3170741A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
CA3187061A1 (en) | 2020-08-06 | 2022-02-10 | Karsten Beckmann | Binding agents for coronavirus s protein |
WO2022040482A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
WO2022047046A1 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Methods of detecting trbc1 or trbc2 |
JP2023542080A (en) | 2020-08-26 | 2023-10-05 | マレンゴ・セラピューティクス,インコーポレーテッド | Multifunctional molecules that bind to calreticulin and their uses |
KR20230074144A (en) | 2020-08-26 | 2023-05-26 | 마렝고 테라퓨틱스, 인크. | Antibody molecules that bind to NKp30 and uses thereof |
CA3192251A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
CA3190349A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia |
MX2023003328A (en) | 2020-09-24 | 2023-03-27 | Hoffmann La Roche | Mammalian cell lines with gene knockout. |
KR20230080437A (en) | 2020-10-02 | 2023-06-07 | 젠맵 에이/에스 | Antibodies capable of binding ROR2 and bispecific antibodies binding ROR2 and CD3 |
UY39467A (en) | 2020-10-13 | 2022-04-29 | Janssen Biotech Inc | BIOENGINEERED T-CELL-MEDIATED IMMUNITY, MATERIALS, AND OTHER METHODS TO MODULATE DIFFERENTIATION GROUP IV AND/OR VIII |
WO2022084915A1 (en) | 2020-10-22 | 2022-04-28 | Janssen Biotech, Inc. | Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses |
JP2023548375A (en) | 2020-11-04 | 2023-11-16 | メルス ナムローゼ フェンノートシャップ | Means and methods for treating subjects with ERBB3 mutation-positive cancer |
US20240010748A1 (en) | 2020-11-10 | 2024-01-11 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibody |
EP4259660A1 (en) | 2020-12-10 | 2023-10-18 | LAVA Therapeutics N.V. | Antibodies that bind gamma-delta t cell receptors |
EP4263604A1 (en) | 2020-12-15 | 2023-10-25 | Merus N.V. | Treatment of cancers with an antibody that binds lgr5 and egfr |
WO2022129120A1 (en) | 2020-12-17 | 2022-06-23 | F. Hoffmann-La Roche Ag | Anti-hla-g antibodies and use thereof |
MX2023007309A (en) | 2020-12-18 | 2023-08-14 | Merus Nv | Antibody composition. |
WO2022129313A1 (en) | 2020-12-18 | 2022-06-23 | F. Hoffmann-La Roche Ag | Precursor proteins and kit for targeted therapy |
JP2024501662A (en) | 2020-12-22 | 2024-01-15 | エフ. ホフマン-ラ ロシュ アーゲー | Oligonucleotide targeting XBP1 |
CA3207090A1 (en) | 2021-01-06 | 2022-07-14 | F. Hoffmann-La Roche Ag | Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody |
WO2022148853A1 (en) | 2021-01-11 | 2022-07-14 | F. Hoffmann-La Roche Ag | Immunoconjugates |
JP2024512240A (en) | 2021-02-18 | 2024-03-19 | エフ. ホフマン-ラ ロシュ アーゲー | Methods for elucidating complex multistep antibody interactions |
CA3209454A1 (en) | 2021-02-26 | 2022-09-01 | Robertus Cornelis ROOVERS | Antibodies that bind cd123 and gamma-delta t cell receptors |
WO2022184659A1 (en) | 2021-03-01 | 2022-09-09 | Quadrucept Bio Limited | Antibody domains & multimers |
IL305736A (en) | 2021-03-09 | 2023-11-01 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cldn6 |
EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
EP4314056A1 (en) | 2021-03-24 | 2024-02-07 | Janssen Biotech, Inc. | Proteins comprising cd3 antigen binding domains and uses thereof |
WO2022206872A1 (en) | 2021-03-31 | 2022-10-06 | 江苏恒瑞医药股份有限公司 | Truncated taci polypeptide and fusion protein and use thereof |
EP4314061A1 (en) | 2021-03-31 | 2024-02-07 | Merus N.V. | Novel multispecific antibodies |
CN117597359A (en) | 2021-04-08 | 2024-02-23 | 马伦戈治疗公司 | Multifunctional molecules binding to TCR and uses thereof |
WO2022228706A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
KR20240005691A (en) | 2021-04-30 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | Dosage for combination therapy with anti-CD20/anti-CD3 bispecific antibody and anti-CD79B antibody drug conjugate |
BR112023021089A2 (en) | 2021-05-07 | 2023-12-12 | Genmab As | PHARMACEUTICAL COMPOSITION, METHOD FOR TREATING A DISEASE, METHOD FOR TREATING CANCER IN AN INDIVIDUAL, USE OF THE PHARMACEUTICAL COMPOSITION, UNIT DOSAGE FORM, KIT OF PARTS, AND, METHOD FOR PREPARING A PHARMACEUTICAL COMPOSITION |
EP4339207A1 (en) | 2021-05-12 | 2024-03-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof |
AU2022273737A1 (en) | 2021-05-14 | 2023-11-16 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Antigen-binding molecule |
CA3221735A1 (en) | 2021-06-18 | 2022-12-22 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
WO2022268740A1 (en) | 2021-06-21 | 2022-12-29 | Genmab A/S | Combination dosage regime of cd137 and pd-l1 binding agents |
WO2023279092A2 (en) | 2021-07-02 | 2023-01-05 | Genentech, Inc. | Methods and compositions for treating cancer |
TW202317635A (en) | 2021-07-14 | 2023-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Antigen-binding molecule that specifically binds to hgfr and egfr and the pharmaceutical use thereof |
CN117730102A (en) | 2021-07-22 | 2024-03-19 | 豪夫迈·罗氏有限公司 | Heterodimeric Fc domain antibodies |
CA3227537A1 (en) | 2021-07-27 | 2023-02-02 | Morphosys Ag | Combinations of antigen binding molecules |
WO2023010060A2 (en) | 2021-07-27 | 2023-02-02 | Novab, Inc. | Engineered vlrb antibodies with immune effector functions |
IL309120A (en) | 2021-07-28 | 2024-02-01 | Hoffmann La Roche | Methods and compositions for treating cancer |
KR102351147B1 (en) * | 2021-08-02 | 2022-01-14 | 주식회사 바이오뱅크힐링 | Blautia obeum strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof |
KR20240051280A (en) | 2021-09-06 | 2024-04-19 | 젠맵 에이/에스 | Antibodies capable of binding CD27, variants thereof and uses thereof |
KR20240055002A (en) | 2021-09-13 | 2024-04-26 | 얀센 바이오테크 인코포레이티드 | CD33 x Vδ2 multispecific antibody for cancer treatment |
CN117813323A (en) | 2021-09-23 | 2024-04-02 | 江苏恒瑞医药股份有限公司 | Anti-KLB antibodies and uses |
WO2023046322A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceutica Nv | Proteins comprising cd20 binding domains, and uses thereof |
CN117916273A (en) | 2021-09-30 | 2024-04-19 | 江苏恒瑞医药股份有限公司 | Anti-IL 23 antibody fusion proteins and uses |
IL311548A (en) | 2021-10-06 | 2024-05-01 | Merus Nv | Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr |
AR127298A1 (en) | 2021-10-08 | 2024-01-10 | Genmab As | ANTIBODIES THAT BIND CD30 AND CD3 |
WO2023062050A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | New interleukin-7 immunoconjugates |
WO2023062048A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | Alternative pd1-il7v immunoconjugates for the treatment of cancer |
WO2023067138A1 (en) | 2021-10-21 | 2023-04-27 | LAVA Therapeutics N.V. | Uses of gamma delta t cell activating antibodies |
WO2023089083A1 (en) | 2021-11-19 | 2023-05-25 | Merus N.V. | Multispecific binding moieties comprising pd-1 and tgf-brii binding domains |
WO2023089587A1 (en) | 2021-11-22 | 2023-05-25 | Janssen Biotech, Inc. | Compositions comprising enhanced multispecific binding agents for an immune response |
WO2023094282A1 (en) | 2021-11-25 | 2023-06-01 | F. Hoffmann-La Roche Ag | Quantification of low amounts of antibody sideproducts |
AR127887A1 (en) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | ANTIBODIES THAT BIND CD3 AND PLAP |
TW202346353A (en) | 2022-03-07 | 2023-12-01 | 荷蘭商美勒斯公司 | Treatment with an antibody that binds egfr and cmet |
WO2023172133A1 (en) | 2022-03-07 | 2023-09-14 | Merus N.V. | Combination therapy including antibodies that bind egfr and cmet |
WO2023174521A1 (en) | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
US20230414750A1 (en) | 2022-03-23 | 2023-12-28 | Hoffmann-La Roche Inc. | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
TW202404637A (en) | 2022-04-13 | 2024-02-01 | 瑞士商赫孚孟拉羅股份公司 | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
WO2023202967A1 (en) | 2022-04-19 | 2023-10-26 | F. Hoffmann-La Roche Ag | Improved production cells |
WO2023218046A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
WO2023218051A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
EP4285926A1 (en) | 2022-05-30 | 2023-12-06 | LAVA Therapeutics N.V. | Combination treatment for chronic lymphocytic leukemia |
WO2023232961A1 (en) | 2022-06-03 | 2023-12-07 | F. Hoffmann-La Roche Ag | Improved production cells |
EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
EP4292609A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
NL2032398B1 (en) | 2022-07-06 | 2024-01-23 | Academisch Ziekenhuis Leiden | Bispecific antibody and uses thereof |
WO2024030027A1 (en) | 2022-08-05 | 2024-02-08 | Merus N.V. | Means and methods for treating castration-resistant prostate cancer |
WO2024079009A1 (en) | 2022-10-10 | 2024-04-18 | F. Hoffmann-La Roche Ag | Combination therapy of a gprc5d tcb and proteasome inhibitors |
WO2024079015A1 (en) | 2022-10-10 | 2024-04-18 | F. Hoffmann-La Roche Ag | Combination therapy of a gprc5d tcb and imids |
WO2024079010A1 (en) | 2022-10-10 | 2024-04-18 | F. Hoffmann-La Roche Ag | Combination therapy of a gprc5d tcb and cd38 antibodies |
WO2024079069A1 (en) | 2022-10-12 | 2024-04-18 | F. Hoffmann-La Roche Ag | Method for classifying cells |
WO2024094660A1 (en) | 2022-10-31 | 2024-05-10 | Genmab A/S | Cd38 antibodies and uses thereof |
WO2024095173A1 (en) | 2022-11-02 | 2024-05-10 | Janssen Biotech, Inc. | Methods of treating cancers |
WO2024100170A1 (en) | 2022-11-11 | 2024-05-16 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a*02/foxp3 |
WO2024104988A1 (en) | 2022-11-15 | 2024-05-23 | F. Hoffmann-La Roche Ag | Recombinant binding proteins with activatable effector domain |
WO2024104933A1 (en) | 2022-11-15 | 2024-05-23 | F. Hoffmann-La Roche Ag | Antigen binding molecules |
Family Cites Families (208)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
AU600885B2 (en) | 1984-05-25 | 1990-08-30 | Zymogenetics Inc. | Stable DNA constructs |
EP0187045B1 (en) | 1984-12-28 | 1991-07-31 | Elf Atochem S.A. | Radiation curable macromonomer printing inks |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
ATE87659T1 (en) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN. |
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
DE307667T1 (en) | 1987-08-24 | 1991-09-05 | Wacom Co., Ltd., Saitama, Jp | COORDINATE INPUT SYSTEM WITH AN INPUT WRITING PEN. |
US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
FI884924A (en) | 1987-10-28 | 1989-04-29 | Oncogen | HUMANIMMUGLOBULIN SOM PRODUCERATS MED HYBRID-DNA-TEKNIK. |
ATE81724T1 (en) | 1987-11-09 | 1992-11-15 | Becton Dickinson Co | PROCEDURE FOR ANALYZING HAEMATOPOIETIC CELLS IN A SAMPLE. |
JP3040121B2 (en) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | Methods of treating tumor cells by inhibiting growth factor receptor function |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP1892296A1 (en) | 1988-09-02 | 2008-02-27 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
GB8909218D0 (en) | 1989-04-22 | 1989-06-07 | Medical Res Council | Improvements in or relating to enhancers |
EP0402029B1 (en) | 1989-06-08 | 1994-01-12 | The Wistar Institute | Monoclonal antibodies for post exposure treatment of rabies |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
US5030002A (en) | 1989-08-11 | 1991-07-09 | Becton, Dickinson And Company | Method and apparatus for sorting particles with a moving catcher tube |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
CA2351200A1 (en) | 1989-12-01 | 1991-06-13 | Gene Pharming Europe Bv | Production of recombinant polypeptides by bovine species and transgenic methods |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
DE4006630A1 (en) | 1990-03-03 | 1991-09-12 | Behringwerke Ag | HUMANE MONOCLONAL ANTIBODIES AGAINST RABBIT VIRUSES, THEIR PRODUCTION AND USE |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DK0585287T3 (en) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Process for producing specific binding pair elements |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0469897A3 (en) | 1990-07-31 | 1992-11-19 | The Wistar Institute | Engineered antibodies |
IE76732B1 (en) | 1990-08-07 | 1997-11-05 | Becton Dickinson Co | One step test for absolute counts |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0546073T3 (en) | 1990-08-29 | 1998-02-02 | Genpharm Int | Production and use of transgenic, non-human animals capable of forming heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
ATE164395T1 (en) | 1990-12-03 | 1998-04-15 | Genentech Inc | METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES |
JP4146512B2 (en) | 1991-03-01 | 2008-09-10 | ダイアックス コープ. | Small protein |
JP3438889B2 (en) | 1991-03-29 | 2003-08-18 | ジェネンテク,インコーポレイテッド | Method for selecting a recombinant host cell that expresses a desired protein at a high level |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
DE4122599C2 (en) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
EP0523949B1 (en) | 1991-07-15 | 2003-06-25 | The Wellcome Foundation Limited | Production of antibodies |
DE69326967T2 (en) | 1992-01-17 | 2000-06-15 | Lakowicz Joseph R | Phase modulation energy transfer fluoroimmunoassay |
US7067284B1 (en) | 1992-01-27 | 2006-06-27 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
SE9201984D0 (en) | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | IMPROVEMENT IN OPTICAL ASSAYS |
DE69334095T2 (en) | 1992-07-17 | 2007-04-12 | Dana-Farber Cancer Institute, Boston | Method for intracellular binding of targeted molecules |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
DE69233803D1 (en) | 1992-10-28 | 2011-03-31 | Genentech Inc | Use of vascular endothelial growth factor antagonists |
DE669986T1 (en) | 1992-11-13 | 1996-10-10 | Idec Pharma Corp | COMPLETELY FUNCTIONAL CONSENSUS-KOZAK SEQUENCES FOR MAMMAL EXPRESSION. |
AU6498294A (en) | 1993-04-07 | 1994-10-24 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Dna sequence which acts as a chromatin insulator element to protect expressed genes from (cis)-acting regulatory sequences in mammalian cells |
ES2162863T3 (en) | 1993-04-29 | 2002-01-16 | Unilever Nv | PRODUCTION OF ANTIBODIES OR FRAGMENTS (FUNCTIONALIZED) OF THE SAME DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF CAMELIDAE. |
US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
EP0739412B1 (en) | 1993-12-23 | 2002-02-27 | Infigen, Inc. | ungulate EMBRYONIC STEM CELLS AS NUCLEAR DONORS AND NUCLEAR TRANSFER TECHNIQUES TO PRODUCE CHIMERIC AND TRANSGENIC ANIMALS |
DK0744958T3 (en) | 1994-01-31 | 2003-10-20 | Univ Boston | Polyclonal antibody libraries |
FR2717187B1 (en) | 1994-03-10 | 1996-05-31 | Transgene Sa | Combined use of two expression cassettes for the production of a protein of interest. |
US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
JPH08116978A (en) | 1994-10-18 | 1996-05-14 | Nisshinbo Ind Inc | Preparation of antibody fab library |
ATE369423T1 (en) | 1994-12-30 | 2007-08-15 | Planet Biotechnology Inc | METHOD FOR PRODUCING IMMUNOGLOBULINS CONTAINING PROTECTIVE PROTEINS AND USE THEREOF |
US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US6825396B2 (en) | 1996-06-12 | 2004-11-30 | Board Of Trustees Operating Michigan State University | Methods for tissue specific synthesis of protein in eggs of transgenic hens |
DE69718341T2 (en) | 1996-10-08 | 2003-10-30 | Bisys B V U | METHOD AND MEANS FOR SELECTING PEPTIDES AND PROTEINS WITH SPECIFIC AFFINITY TO A TARGET MOLECULE |
GB9621113D0 (en) | 1996-10-10 | 1996-11-27 | Univ Southampton | Transgenic fish |
IL130160A0 (en) | 1996-12-02 | 2000-06-01 | Univ Wake Forest | Inactivation of HIV co-receptors as therapy for HIV infection |
PT971946E (en) | 1997-01-21 | 2006-11-30 | Gen Hospital Corp | Selection of proteins using rna-protein fusions |
WO1998039416A1 (en) | 1997-03-06 | 1998-09-11 | Infigen, Inc. | Method of cloning animals |
RO120148B1 (en) | 1997-03-14 | 2005-09-30 | Idec Pharmaceuticals Corporation | Vector system and method for integrating a dna fragment in the mammalian cells genome |
US6080912A (en) | 1997-03-20 | 2000-06-27 | Wisconsin Alumni Research Foundation | Methods for creating transgenic animals |
AU743758B2 (en) | 1997-04-07 | 2002-02-07 | Genentech Inc. | Anti-VEGF antibodies |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
ES2246069T3 (en) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | PROCEDURE FOR THE PREPARATION OF MULTI-SPECIFIC ANTIBODIES THAT HAVE COMMON AND MULTIMERIC COMPONENTS. |
CA2290485C (en) | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
AU747609B2 (en) | 1997-09-23 | 2002-05-16 | Oxford Biomedica (Uk) Limited | Expression of genes in hematopoietic stem cells in hischaemic conditions |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
WO1999023221A2 (en) | 1997-10-27 | 1999-05-14 | Unilever Plc | Multivalent antigen-binding proteins |
DE69823652D1 (en) | 1997-11-26 | 2004-06-09 | Mitsubishi Precision Co Ltd | INFORMATION MANAGEMENT SYSTEM |
CA2325721A1 (en) | 1998-03-30 | 1999-10-07 | Research Development Foundation | Corticotropin releasing factor receptor 1-deficient mice |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
EP1151002A4 (en) | 1999-01-29 | 2002-05-02 | Imclone Systems Inc | Antibodies specific to kdr and uses thereof |
ATE447617T1 (en) | 1999-04-15 | 2009-11-15 | Crucell Holland Bv | USE OF RECOMBINANT PROTEINS IN HUMAN CELLS |
DK1054018T3 (en) | 1999-05-18 | 2009-05-18 | Dyax Corp | Fab fragment libraries and method of using them |
US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
ES2329437T3 (en) | 1999-06-25 | 2009-11-26 | Genentech, Inc. | ANTI-ERBB2 ANTIBODIES HUMANIZED AND TREATMENT WITH ANTI-ERBB2 ANTIBODIES. |
WO2001019394A2 (en) | 1999-09-15 | 2001-03-22 | Therapeutic Human Polyclonals, Inc. | Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds |
US6180357B1 (en) | 1999-10-08 | 2001-01-30 | Arius Research, Inc. | Individualized patient-specific anti-cancer antibodies |
WO2001027279A1 (en) | 1999-10-12 | 2001-04-19 | Cambridge Antibody Technology | Human anti-adipocyte monoclonal antibodies and their use |
EP2278022A3 (en) | 1999-11-01 | 2011-05-18 | Novartis Vaccines and Diagnostics, Inc. | Expression vectors, transfection systems, and method of use thereof |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
JP2003518391A (en) | 1999-12-27 | 2003-06-10 | クルセル ホランド ベー ヴェー | Methods of using native epitopes to select developed binding members from a library of mutant proteins capable of binding to the epitope |
WO2001064929A1 (en) | 2000-02-29 | 2001-09-07 | Auburn University | Production of antibodies in transgenic plastids |
US20040180046A1 (en) | 2000-04-26 | 2004-09-16 | Jeff Himawan | Bispecific molecules and uses thereof |
EP1297016B1 (en) | 2000-05-12 | 2006-03-22 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage |
ATE411387T1 (en) | 2000-05-16 | 2008-10-15 | Univ Jefferson | RABIES VIRUS-SPECIFIC NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES AND NUCLEIC ACID AND RELATED METHODS |
JP4955185B2 (en) | 2000-06-29 | 2012-06-20 | アボット・ラボラトリーズ | Bispecific antibodies and methods for making and using the same |
EP1184458A1 (en) | 2000-08-28 | 2002-03-06 | U-BISys B.V. | Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof |
EP1188771A1 (en) | 2000-09-15 | 2002-03-20 | U-BISys B.V. | Libraries of human heavy chain variable fragments in a functional format |
US7737258B2 (en) | 2000-10-18 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
AU3942202A (en) | 2000-11-30 | 2002-06-11 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
FR2817875B1 (en) | 2000-12-07 | 2005-03-18 | Technopharm | PROCESS FOR THE PREPARATION OF A HUMAN MONOCLONAL ANTIBODY, FRAGMENTS THEREOF OR ANTIBODIES COMPRISING SUCH FRAGMENTS, THE ANTIBODIES THUS OBTAINED AND THEIR USE |
WO2002059297A2 (en) | 2001-01-25 | 2002-08-01 | Evolva Biotech A/S | A library of a collection of cells |
SG141239A1 (en) | 2001-01-26 | 2008-04-28 | Selexis Sa | Matrix attachment regions and methods for use thereof |
AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
WO2002076196A1 (en) | 2001-03-22 | 2002-10-03 | Abbott Gmbh & Co. Kg | Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
CZ200438A3 (en) | 2001-06-13 | 2004-06-16 | Genmab A/S | The title is not available |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
US7329530B2 (en) | 2001-06-15 | 2008-02-12 | Crucell Holland B.V. | Chimaeric phages |
WO2004003211A1 (en) | 2002-06-26 | 2004-01-08 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
DE60237282D1 (en) | 2001-06-28 | 2010-09-23 | Domantis Ltd | DOUBLE-SPECIFIC LIGAND AND ITS USE |
DE60236332D1 (en) | 2001-07-04 | 2010-06-17 | Chromagenics Bv | DNA sequences with anti-repressor activity |
AU2002332600B2 (en) | 2001-08-21 | 2007-03-22 | Thomas Jefferson University | Recombinant antibodies, and compositions and methods for making and using the same |
NZ530852A (en) | 2001-08-27 | 2006-11-30 | Genentech Inc | Methods and compositions for recombinantly producing functional antibodies or antibody fragments in prokaryotic and eukaryotic host cells |
NZ533056A (en) | 2001-11-16 | 2007-12-21 | Biogen Idec Inc | Polycistronic expression of antibodies |
NZ533226A (en) | 2001-11-30 | 2006-05-26 | Crucell Holland B | Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation |
EP1456651B1 (en) | 2001-11-30 | 2008-05-07 | National Research Council Of Canada | Self-assembly molecules |
GB0130267D0 (en) | 2001-12-19 | 2002-02-06 | Neutec Pharma Plc | Focussed antibody technology |
US7244592B2 (en) | 2002-03-07 | 2007-07-17 | Dyax Corp. | Ligand screening and discovery |
GB2387030A (en) | 2002-03-26 | 2003-10-01 | Thales Plc | Compensation of mutual coupling in array antenna systems |
EP1510943A4 (en) | 2002-05-31 | 2007-05-09 | Celestar Lexico Sciences Inc | Interaction predicting device |
AU2003239966B9 (en) | 2002-06-03 | 2010-08-26 | Genentech, Inc. | Synthetic antibody phage libraries |
AU2003243059A1 (en) | 2002-06-14 | 2003-12-31 | Chromagenics B.V. | Use of repression blocking sequences in methods for enhancing gene expression |
CA2722998C (en) | 2002-06-14 | 2014-12-02 | Chromagenics B.V. | A method for simultaneous production of multiple proteins; vectors and cells for use therein |
US20080241166A1 (en) | 2002-06-28 | 2008-10-02 | Domantis Limited | Ligands that bind a receptor |
EP1521887B1 (en) | 2002-07-10 | 2010-07-28 | Agostino Di Trapani | Building block |
DK2314629T4 (en) | 2002-07-18 | 2023-02-06 | Merus Nv | RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES |
BRPI0406678A (en) | 2003-01-07 | 2005-12-20 | Symphogen As | Method for producing recombinant polyclonal proteins |
EP1439234A1 (en) | 2003-01-08 | 2004-07-21 | ARTEMIS Pharmaceuticals GmbH | Targeted transgenesis using the rosa26 locus |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
AU2004242614B2 (en) | 2003-05-30 | 2011-09-22 | Merus N.V. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
EP2322547A1 (en) | 2003-06-25 | 2011-05-18 | Crucell Holland B.V. | Myeloid cell-specific lectin |
SG128680A1 (en) | 2003-07-22 | 2007-01-30 | Crucell Holland Bv | Binding molecules against sars-coronavirus and uses thereof |
ES2378767T3 (en) | 2003-12-23 | 2012-04-17 | Crucell Holland B.V. | Human binding molecule against CD1a |
ES2646560T3 (en) | 2004-01-20 | 2017-12-14 | Merus N.V. | Binding Protein Blends |
ES2426725T3 (en) | 2004-05-27 | 2013-10-24 | Crucell Holland B.V. | Method to identify binding molecules that can neutralize rabies virus |
EA010350B1 (en) | 2004-06-03 | 2008-08-29 | Новиммун С.А. | Anti-cd3 antibodies and methods of use thereof |
JP2008511337A (en) | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | Heteromultimeric molecule |
EP1799259B1 (en) | 2004-10-12 | 2012-12-05 | Crucell Holland B.V. | Binding molecules for the detection of cancer |
JP4487068B2 (en) | 2004-10-12 | 2010-06-23 | 国立大学法人 岡山大学 | Method for producing mutant protein by controlling gene mutation function of cell |
ATE550037T1 (en) | 2004-11-11 | 2012-04-15 | Crucell Holland Bv | COMPOSITIONS AGAINST THE SARS CORONAVIRUS AND THEIR USES |
JP5620626B2 (en) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | Polypeptide production method by association control |
EP1874817A2 (en) | 2005-04-29 | 2008-01-09 | Innate Pharma | Transgenic animals and methods of making recombinant antibodies |
CA2608058C (en) | 2005-05-12 | 2013-09-10 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
EP1893645A1 (en) | 2005-06-23 | 2008-03-05 | Crucell Holland B.V. | Optimization of west nile virus antibodies |
WO2007031550A2 (en) | 2005-09-15 | 2007-03-22 | Crucell Holland B.V. | Method for preparing immunoglobulin libraries |
BRPI0619056A2 (en) | 2005-11-28 | 2011-09-20 | Genmab As | monovalent antibody, method for preparing and producing a monovalent antibody, nucleic acid construct, host cell, immunoconjugate, use of a monovalent antibody, and pharmaceutical composition |
ZA200804337B (en) * | 2005-11-28 | 2009-11-25 | Genmab As | Recombinant monovalent antibodies and methods for production thereof |
AR060070A1 (en) | 2006-03-24 | 2008-05-21 | Merck Patent Gmbh | HETERODYMERIC PROTEIN DOMAINS OBTAINED BY ENGINEERING |
AU2007235496B2 (en) | 2006-03-31 | 2013-11-21 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
EP3018142A1 (en) | 2006-06-06 | 2016-05-11 | Crucell Holland B.V. | Human binding molecules having killing activity against staphylococci and uses thereof |
MX2008014978A (en) | 2006-06-06 | 2008-12-09 | Crucell Holland Bv | Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof. |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
PL2059533T3 (en) | 2006-08-30 | 2013-04-30 | Genentech Inc | Multispecific antibodies |
EA017203B1 (en) | 2006-09-07 | 2012-10-30 | Круселл Холланд Б.В. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
PL2769992T3 (en) | 2006-10-02 | 2021-08-02 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
US8290739B2 (en) | 2006-10-20 | 2012-10-16 | Amfit, Inc. | Method for determining relative mobility of regions of an object |
RU2448979C2 (en) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Human antibodies to delta-like human ligand-4 |
CN104497143B (en) | 2007-03-29 | 2020-08-25 | 健玛保 | Bispecific antibody and method for producing same |
ITMI20071522A1 (en) | 2007-07-27 | 2009-01-28 | Areta Internat S R L | IDIOTYPIC VACCINE |
KR20100058541A (en) | 2007-08-15 | 2010-06-03 | 아뮤닉스 인코포레이티드 | Compositions and methods for modifying properties of biologically active polypeptides |
CA2697193C (en) | 2007-09-14 | 2017-06-06 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
EP2211903A4 (en) | 2007-10-17 | 2011-07-06 | Nuvelo Inc | Antibodes to cll-1 |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
PL2235064T3 (en) * | 2008-01-07 | 2016-06-30 | Amgen Inc | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
AU2009211148B2 (en) | 2008-02-05 | 2014-08-28 | Zymeworks Inc. | Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics |
KR102261586B1 (en) | 2008-06-27 | 2021-06-08 | 메뤼스 엔.페. | Antibody producing non-human mammals |
SG172977A1 (en) * | 2009-01-26 | 2011-08-29 | Genmab As | Methods for producing mixtures of antibodies |
MA33198B1 (en) | 2009-03-20 | 2012-04-02 | Genentech Inc | ANTI-HER DI-SPECIFIC ANTIBODIES |
ES2708124T3 (en) | 2009-04-27 | 2019-04-08 | Oncomed Pharm Inc | Procedure for preparing heteromultimeric molecules |
NZ596032A (en) | 2009-05-11 | 2013-09-27 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
CN103833855A (en) | 2009-06-26 | 2014-06-04 | 瑞泽恩制药公司 | Readily isolated bispecific antibodies with native immunoglobulin format |
US8765900B2 (en) | 2009-08-27 | 2014-07-01 | Bayer Materialscience Llc | Aliphatic moisture-curable resins, coating compositions, and related processes |
US9493578B2 (en) * | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
ES2688978T3 (en) | 2009-11-23 | 2018-11-07 | Amgen Inc. | Fc monomeric antibody |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US9527926B2 (en) * | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
AU2011288412A1 (en) * | 2010-08-13 | 2013-02-21 | Medimmune Limited | Monomeric polypeptides comprising variant Fc regions and methods of use |
CA2808482C (en) | 2010-08-16 | 2021-10-26 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
EP2635607B1 (en) * | 2010-11-05 | 2019-09-04 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
DE12192727T1 (en) | 2011-02-25 | 2013-07-11 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
CA2812739A1 (en) | 2011-03-25 | 2012-10-04 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
JP2013004215A (en) | 2011-06-14 | 2013-01-07 | Hitachi Ltd | Lithium-ion secondary battery |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
MX353278B (en) | 2012-03-06 | 2018-01-05 | Regeneron Pharma | Common light chain mouse. |
CN114163530A (en) * | 2012-04-20 | 2022-03-11 | 美勒斯公司 | Methods and means for producing immunoglobulin-like molecules |
CN104582476B (en) | 2012-06-05 | 2017-03-08 | 瑞泽恩制药公司 | The method preparing complete people bi-specific antibody using common light chain |
PL2900694T3 (en) * | 2012-09-27 | 2018-12-31 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
UY35148A (en) * | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
US10798961B2 (en) | 2013-03-15 | 2020-10-13 | Altria Client Services Llc | Functional food and beverage compositions with improved taste through the use of sensates |
CA2991880A1 (en) | 2015-07-10 | 2017-01-19 | Merus N.V. | Human cd3 binding antibody |
-
2013
- 2013-04-19 CN CN202111365429.7A patent/CN114163530A/en active Pending
- 2013-04-19 KR KR1020207030488A patent/KR20200126007A/en active Application Filing
- 2013-04-19 CN CN201710637343.2A patent/CN107383197B/en active Active
- 2013-04-19 NZ NZ799532A patent/NZ799532A/en unknown
- 2013-04-19 DK DK13720614.0T patent/DK2838917T3/en active
- 2013-04-19 PT PT13720614T patent/PT2838917T/en unknown
- 2013-04-19 KR KR1020147032231A patent/KR102104601B1/en active IP Right Grant
- 2013-04-19 SG SG10201913634VA patent/SG10201913634VA/en unknown
- 2013-04-19 EP EP13720614.0A patent/EP2838917B1/en active Active
- 2013-04-19 EA EA202090591A patent/EA202090591A3/en unknown
- 2013-04-19 CN CN201380032190.9A patent/CN104520319B/en active Active
- 2013-04-19 EA EA201491909A patent/EA035344B1/en not_active IP Right Cessation
- 2013-04-19 CA CA2870821A patent/CA2870821C/en active Active
- 2013-04-19 RS RSP20190999 patent/RS59260B1/en unknown
- 2013-04-19 WO PCT/NL2013/050293 patent/WO2013157953A1/en active Application Filing
- 2013-04-19 CN CN201380032276.1A patent/CN104520320B/en active Active
- 2013-04-19 SG SG10201607371UA patent/SG10201607371UA/en unknown
- 2013-04-19 NZ NZ772318A patent/NZ772318A/en unknown
- 2013-04-19 PL PL13720614T patent/PL2838917T3/en unknown
- 2013-04-19 PT PT13720615T patent/PT2838918T/en unknown
- 2013-04-19 US US13/866,756 patent/US9248182B2/en active Active
- 2013-04-19 SG SG11201406772YA patent/SG11201406772YA/en unknown
- 2013-04-19 EP EP19178196.2A patent/EP3594233A1/en active Pending
- 2013-04-19 KR KR1020237019940A patent/KR20230093359A/en not_active Application Discontinuation
- 2013-04-19 NZ NZ630551A patent/NZ630551A/en unknown
- 2013-04-19 LT LTEP13720615.7T patent/LT2838918T/en unknown
- 2013-04-19 JP JP2015506927A patent/JP6272299B2/en active Active
- 2013-04-19 MX MX2014012701A patent/MX360110B/en active IP Right Grant
- 2013-04-19 AU AU2013249985A patent/AU2013249985B2/en active Active
- 2013-04-19 SI SI201331553T patent/SI2838917T1/en unknown
- 2013-04-19 DK DK13720615.7T patent/DK2838918T3/en active
- 2013-04-19 KR KR1020237019942A patent/KR20230091201A/en not_active Application Discontinuation
- 2013-04-19 KR KR1020207001067A patent/KR102269650B1/en active IP Right Grant
- 2013-04-19 PL PL13720615T patent/PL2838918T3/en unknown
- 2013-04-19 SG SG10201607369QA patent/SG10201607369QA/en unknown
- 2013-04-19 ES ES13720615T patent/ES2740749T3/en active Active
- 2013-04-19 EP EP13720615.7A patent/EP2838918B1/en active Active
- 2013-04-19 HU HUE13720614A patent/HUE045944T2/en unknown
- 2013-04-19 KR KR1020207011173A patent/KR102382304B1/en active IP Right Grant
- 2013-04-19 LT LTEP13720614.0T patent/LT2838917T/en unknown
- 2013-04-19 CA CA2871068A patent/CA2871068C/en active Active
- 2013-04-19 AU AU2013249986A patent/AU2013249986B2/en active Active
- 2013-04-19 ES ES13720614T patent/ES2743399T3/en active Active
- 2013-04-19 HU HUE13720615A patent/HUE045945T2/en unknown
- 2013-04-19 WO PCT/NL2013/050294 patent/WO2013157954A1/en active Application Filing
- 2013-04-19 KR KR1020227011508A patent/KR102545770B1/en active Application Filing
- 2013-04-19 SI SI201331534T patent/SI2838918T1/en unknown
- 2013-04-19 JP JP2015506928A patent/JP6393255B2/en active Active
- 2013-04-19 KR KR1020147032229A patent/KR102171431B1/en active IP Right Grant
- 2013-04-19 US US14/395,330 patent/US20150139996A1/en not_active Abandoned
- 2013-04-19 RS RSP20191034 patent/RS59263B1/en unknown
- 2013-04-19 SG SG11201406770WA patent/SG11201406770WA/en unknown
- 2013-04-19 US US13/866,747 patent/US9248181B2/en active Active
- 2013-04-19 EP EP19177410.8A patent/EP3594232A1/en active Pending
- 2013-04-19 US US14/395,325 patent/US20150196637A1/en not_active Abandoned
- 2013-04-19 NZ NZ630568A patent/NZ630568A/en unknown
- 2013-04-19 CN CN201810296908.XA patent/CN108586610A/en active Pending
- 2013-04-19 MX MX2014012700A patent/MX360109B/en active IP Right Grant
- 2013-04-19 EA EA201491908A patent/EA201491908A1/en unknown
- 2013-04-19 SG SG10201913376XA patent/SG10201913376XA/en unknown
- 2013-11-15 US US14/081,848 patent/US9358286B2/en active Active
-
2014
- 2014-10-20 MX MX2018012766A patent/MX2018012766A/en unknown
- 2014-10-20 MX MX2018012769A patent/MX2018012769A/en unknown
- 2014-10-27 ZA ZA2014/07835A patent/ZA201407835B/en unknown
- 2014-10-27 ZA ZA2014/07834A patent/ZA201407834B/en unknown
-
2015
- 2015-07-10 HK HK15106583.3A patent/HK1206039A1/en unknown
- 2015-07-15 HK HK15106743.0A patent/HK1206041A1/en unknown
- 2015-12-18 US US14/974,581 patent/US9758805B2/en active Active
-
2016
- 2016-05-16 US US15/155,743 patent/US10329596B2/en active Active
-
2017
- 2017-04-25 US US15/496,807 patent/US10337045B2/en active Active
- 2017-12-28 JP JP2017254422A patent/JP6639464B2/en active Active
-
2018
- 2018-02-23 AU AU2018201326A patent/AU2018201326B2/en active Active
- 2018-02-23 AU AU2018201325A patent/AU2018201325B2/en active Active
- 2018-08-24 JP JP2018157537A patent/JP6781740B2/en active Active
-
2019
- 2019-05-20 US US16/417,379 patent/US10752929B2/en active Active
- 2019-08-02 HR HRP20191409 patent/HRP20191409T1/en unknown
- 2019-08-05 CY CY20191100831T patent/CY1122153T1/en unknown
- 2019-08-09 HR HRP20191446 patent/HRP20191446T1/en unknown
- 2019-08-28 CY CY20191100914T patent/CY1122118T1/en unknown
- 2019-12-24 JP JP2019233206A patent/JP2020089366A/en active Pending
-
2020
- 2020-07-21 US US16/934,925 patent/US20210071222A1/en active Pending
- 2020-08-20 JP JP2020139295A patent/JP2020202854A/en active Pending
-
2023
- 2023-02-28 JP JP2023030194A patent/JP2023060019A/en active Pending
- 2023-05-16 US US18/318,507 patent/US11926859B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1206041A1 (en) | Methods and means for the production of ig-like molecules | |
HK1210189A1 (en) | Method for the production and selection of molecules comprising at least two different entities and uses thereof | |
IL234460B (en) | Multispecific antigen-binding molecules and uses thereof | |
HK1208880A1 (en) | Method for producing monomeric and multimeric molecules and uses thereof | |
IL234234B (en) | Ang2-binding molecules | |
SG11201502932TA (en) | Compounds and methods for the production of suckerin and uses thereof | |
GB201503017D0 (en) | Method and system for the production of nanoparticles | |
ZA201502937B (en) | Process for the preparation of hydrocarbons | |
PL2877587T3 (en) | Method for the production of methane and apparatus suitable therefore | |
HUE046533T2 (en) | Means and methods for methane production | |
HK1210225A1 (en) | Procedure for the production of tiacumicin | |
HUP1200171A1 (en) | Methods for the production of polypeptides | |
GB201202060D0 (en) | Novel compounds and methods for their production |